Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People Briefs: Louis Jacques To Leave CMS; FDA, MHRA Appointments

This article was originally published in The Gray Sheet

Executive Summary

Louis Jacques, who directs CMS’ coverage office, will leave the agency at the end of the month. FDA appoints acting deputy chief scientist. The U.K. Medicines and Healthcare products Regulatory Agency names clinical director of medical devices. More people briefs.

You may also be interested in...



People Briefs: FDA Turnover; Appointments At Boston Scientific, Dysis Medical

FDA Chief Scientist Jesse Goodman leaves agency. New FDA deputy commissioner for global regulatory operations and policy appointed. Boston Scientific names new chief medical officer. More people briefs.

Final Coverage-With-Evidence-Development Guidance Delayed By CMS Staff Cuts

The CMS coverage and analysis group has had to divert its attention from finishing a CED guidance to finalizing proposed changes to the process for awarding Medicare coverage for IDE trials, primarily due to staff cuts, says Louis Jacques, who heads the group.

FDA-CMS Parallel Review Saves Time, Clinical Trial Costs, Participant Says

Exact Sciences, one of the first companies to volunteer for a pilot program launched in 2011 testing FDA-CMS parallel review, says its experience with the process so far is very positive. Agency officials are planning to review experiences with the program to make improvements.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033625

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel